Literature DB >> 9588928

Sublethal damage repair times for a late-responding tissue relevant to brachytherapy (and external-beam radiotherapy): implications for new brachytherapy protocols.

D Brenner1, E Armour, P Corry, E Hall.   

Abstract

PURPOSE: Data were analyzed from recent experiments with the end point of late rectal obstruction in rats, involving acute and various protracted radiation exposures. Because the end point is of direct relevance both for brachytherapy as well as external beam radiotherapy, the goal was to estimate the linear-quadratic (LQ) parameters alpha/beta and T1/2, which are of importance for designing improved protraction/fractionation schemes. METHODS AND MATERIALS: The data were fit to the LQ model, both in its standard form and in a form in which two different components of sublethal damage repair-fast and slow-are assumed. The design of the experiments was such that both slow and reasonably fast sublethal damage repair components should be separately estimated, if they were contributing to a significant degree.
RESULTS: LQ parameter estimates were alpha/beta = 4.6 Gy [4.0, 5.5] and T1/2 = 70.2 min [59.1, 91.4]. Despite the experimental design facilitating detection of a rapid component of repair, no statistically robust evidence for a very fast repair component was found.
CONCLUSIONS: The long estimated repair time for a late-responding normal-tissue end point with direct relevance to brachytherapy suggests a variety of possible brachytherapy protocols that may be more efficacious than continuous low dose rate irradiation. Just as a difference in alpha/beta ratios between early- and late-responding tissues are a central tenet in radiotherapy, so corresponding differences in T1/2 values have the potential to be exploited, particularly for brachytherapy.

Entities:  

Mesh:

Year:  1998        PMID: 9588928     DOI: 10.1016/s0360-3016(98)00029-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Pulsed dose rate brachytherapy.

Authors:  A Polo
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

2.  Dosimetric effect of tissue heterogeneity for (125)I prostate implants.

Authors:  Susana Maria Oliveira; Nuno José Teixeira; Lisete Fernandes; Pedro Teles; Pedro Vaz
Journal:  Rep Pract Oncol Radiother       Date:  2014-04-16

3.  Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.

Authors:  Himanshu R Lukka; Stephanie L Pugh; Deborah W Bruner; Jean-Paul Bahary; Colleen A F Lawton; Jason A Efstathiou; Rajat J Kudchadker; Lee E Ponsky; Samantha A Seaward; Ian S Dayes; Darindra D Gopaul; Jeff M Michalski; Guila Delouya; Irving D Kaplan; Eric M Horwitz; Mack Roach; Wayne H Pinover; David C Beyer; John O Amanie; Howard M Sandler; Lisa A Kachnic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-18       Impact factor: 7.038

4.  Ku-dependent non-homologous end-joining as the major pathway contributes to sublethal damage repair in mammalian cells.

Authors:  Min Liu; Solah Lee; Bailong Liu; Hongyan Wang; Lihua Dong; Ya Wang
Journal:  Int J Radiat Biol       Date:  2015-08-27       Impact factor: 2.694

5.  Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients.

Authors:  Christos Nanos; Vasilios Souftas; Athanasios Zissimopoulos; Michael I Koukourakis
Journal:  Radiat Oncol J       Date:  2022-06-20

6.  Equivalent normalized total dose estimates in cyberknife radiotherapy dose delivery in prostate cancer hypofractionation regimens.

Authors:  H Sudahar; P G G Kurup; V Murali; P Mahadev; J Velmurugan
Journal:  J Med Phys       Date:  2012-04

7.  Acute toxicity profile in prostate cancer with conventional and hypofractionated treatment.

Authors:  Gustavo Arruda Viani; Lucas Bernardes Godoy da Silva; Bruna Bueno da Silva; Yuri Bonicelli Crempe; Vinicius Spazzapan Martins; Ricardo Jose Rambaiolo Ferrari; Mariana Colbachini Pólo; Bruno Thiago Rossi; Elton Suguikawa; Giseli Correa Zulliani; Eduardo Jose Stefano
Journal:  Radiat Oncol       Date:  2013-04-21       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.